Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT01051349
First received: January 15, 2010
Last updated: August 15, 2016
Last verified: August 2016
  Purpose
Primary Objective is to assess the safety of extended treatment with Daclizumab High Yield Process (DAC HYP, BIIB019) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS). Secondary Objective is to assess the long-term immunogenicity of DAC HYP and to assess the durability of response to DAC HYP in preventing multiple sclerosis (MS) relapse, slowing disability progression, and reducing new MS lesion formation in this study population.

Condition Intervention Phase
Relapsing-Remitting Multiple Sclerosis
Biological: BIIB019 (Daclizumab)
Biological: trivalent seasonal influenza vaccine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)

Resource links provided by NLM:


Further study details as provided by Biogen:

Primary Outcome Measures:
  • Adverse Events (AEs), Serious AEs (SAEs) and discontinuation of DAC HYP due to AEs, and withdrawals due to AEs. [ Time Frame: 288 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Annual change in total number of new or newly enlarging T2 hyperintense lesions [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    Evaluated by magnetic resonance imaging (MRI) by a central reader.

  • Annual change in volume of new or newly enlarging T2 hyperintense lesions) [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    Evaluated by magnetic resonance imaging (MRI) by a central reader.

  • Annual change in total number of Gadolinium-enhancing lesions [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    Evaluated by magnetic resonance imaging (MRI) by a central reader.

  • Annual change in number of T1 hypointense lesions [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    Evaluated by magnetic resonance imaging (MRI) by a central reader.

  • Annual change in volume of new gadolinium-enhancing lesions. [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    Evaluated by magnetic resonance imaging (MRI) by a central reader.

  • Annual change in volume of T1 hypointense lesions [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    Evaluated by magnetic resonance imaging (MRI) by a central reader.

  • Total brain volume [ Time Frame: From Baseline through 288 weeks ] [ Designated as safety issue: No ]
    To assess brain atrophy, total brain volume will be measured by magnetic resonance imaging (MRI) and analyzed by a central reader.

  • Number of participants with antibodies to DAC HYP. [ Time Frame: 288 weeks ] [ Designated as safety issue: Yes ]
  • Annualized Relapse Rate (ARR) [ Time Frame: 288 weeks ] [ Designated as safety issue: Yes ]
    Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The ARR will be calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.

  • Number of participants with sustained disability progression [ Time Frame: 288 weeks ] [ Designated as safety issue: No ]
    Sustained disability progression defined by at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from a baseline EDSS ≥1.0 that is sustained for 12 weeks, or at least a 1.5-point increase on the EDSS from a baseline EDSS <1.0 that is sustained for 12 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10, with higher scores indicating more disability.


Enrollment: 410
Study Start Date: March 2010
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIIB019
150 mg subcutaneous injection every 4 weeks for up to 6 years or until availability of commercial product (whichever is sooner).
Biological: BIIB019 (Daclizumab)
Administered as specified in the treatment arm.
Other Names:
  • Daclizumab High Yield Process
  • DAC HYP
Biological: trivalent seasonal influenza vaccine
All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site

Detailed Description:
This study will provide participants who complete Study 205MS202 (NCT00870740) with the option to receive continued open-label Daclizumab High Yield Process (DAC HYP) monotherapy and to evaluate the long-term safety, efficacy, and immunogenicity of DAC HYP monotherapy in participants with relapsing remitting multiple sclerosis (RRMS). Approximately 60 to 100 participants will be enrolled into an optional open-label, 16-week autoinjector substudy at a selected subset of sites which will run concurrently during the main study, and will evaluate the systemic exposure and local tolerability of subcutaneous administration of DAC HYP by autoinjector. The 2013-2014 trivalent influenza vaccine will be offered to all eligible participants as an optional substudy to assess the effect of DAC-HYP treatment on the immune response to vaccination,
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Study Eligibility:

Key Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  • Subjects who have completed 52 weeks in Study 205MS202 (NCT00870740) and were compliant with the 205MS202 protocol in the opinion of the Investigator.
  • Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment.

Key Exclusion Criteria:

  • Subjects with any significant change in their medical status from the previous study that would prelude administration of Daclizumab High Yield Process (DAC HYP) as determined by the Investigator including laboratory tests or a current clinically significant condition that, in the opinion of the Investigator, would have excluded the subject's participation in the 205MS201 (NCT00390221) or 205MS202 (NCT00870740) studies. The Investigator must re-review the subject's medical fitness for participation and must consider any diseases that would preclude treatment.
  • Any subject who has permanently discontinued study treatment in Study 205MS202 (NCT00870740) due to an adverse event.
  • Current enrollment in any investigational drug study other than Study 205MS202 (NCT00870740).
  • Ongoing treatment with any approved or experimental disease-modifying treatment for multiple sclerosis.
  • For subjects currently taking valproic acid, carbamazepine, lamotrigine, or phenytoin:

    • Subjects treated with any of these agents for fewer than 6 months prior to study entry are excluded from study participation unless they discontinue the agent(s) prior to study entry.
    • Subjects treated with 2 or more of these agents for more than 6 months prior to study entry are excluded from study participation unless they reduce to ≤1 agent prior to study entry.
    • Subjects who have had dose escalations of one of these agents within the 6 months prior to study entry are excluded from study participation unless they revert to a previous dose that had been used for at least 6 months prior to study entry or unless they discontinue the agent prior to study entry
  • Subjects who are currently receiving treatment with isoniazid, propylthiouracil, or nimesulide at the time of study entry and are not able to discontinue the agent or change to an alternative medication allowed by the protocol.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01051349

  Hide Study Locations
Locations
Czech Republic
Research Site
Brno, Czech Republic, 625 00
Research Site
Brno, Czech Republic, 656 91
Research Site
Hradec Kravlove, Czech Republic, 500 05
Research Site
Prague, Czech Republic, 100 34
Research Site
Teplice, Czech Republic, 415 29
Germany
Research Site
Bayreuth, Germany, 95445
Research Site
Erlangen, Germany, 91054
Research Site
Marburg, Germany, 35033
Research Site
Rostock, Germany, 18147
Hungary
Research Site
Budapest, Hungary, 1076
Research Site
Budapest, Hungary, 1083
Research Site
Budapest, Hungary, 1115
Research Site
Budapest, Hungary, 1125
Research Site
Budapest, Hungary, 1134
Research Site
Debrecen, Hungary, 4031
Research Site
Debrecen, Hungary, 4032
Research Site
Esztergom, Hungary, 2500
Research Site
Gyor, Hungary, 9023
Research Site
Kecskemet, Hungary, 6000
Research Site
Miskolc, Hungary, 3526
Research Site
Miskolc, Hungary, 3533
Research Site
Nyiregyhaza, Hungary, 4400
Research Site
Siofok, Hungary, 8600
India
Research Site
Bangalore, India
Research Site
Hyderabad, India, 500082
Research Site
Kolkata, India, 700068
Research Site
Mumbai, India, 400012
Research Site
Rajastan, India, 302021
Poland
Research Site
Bialystok, Poland, 15-276
Research Site
Bialystok, Poland, 15-420
Research Site
Gdansk, Poland, 80-803
Research Site
Katowice, Poland
Research Site
Krakow, Poland, 31-505
Research Site
Lodz, Poland, 93121
Research Site
Lublin, Poland, 20954
Research Site
Warszawa, Poland, 02-957
Research Site
Warszawa, Poland
Russian Federation
Research Site
Kazan, Russian Federation, 420021
Research Site
Krasnoyarsk, Russian Federation, 660049
Research Site
Moscow, Russian Federation, 107150
Research Site
Moscow, Russian Federation, 115682
Research Site
Moscow, Russian Federation, 127018
Research Site
Nizhniy Novgorod, Russian Federation, 603076
Research Site
Novosibirsk, Russian Federation, 630087
Research Site
Omsk, Russian Federation, 644033
Research Site
Samara, Russian Federation, 443095
Research Site
Smolensk, Russian Federation, 214018
Research Site
St Petersburg, Russian Federation, 194044
Research Site
Ufa, Russian Federation, 450005
Research Site
Yaroskavi, Russian Federation, 150030
Ukraine
Research Site
Chernivtsy, Ukraine, 58018
Research Site
Dnipropetrovsk, Ukraine, 49027
Research Site
Donetsk, Ukraine, 83003
Research Site
Kharkiv, Ukraine, 61068
Research Site
Kharkiv, Ukraine
Research Site
Kiev, Ukraine, 2125
Research Site
Kiev, Ukraine, 3110
Research Site
Poltava, Ukraine, 36024
Research Site
Zaporozhye, Ukraine, 69035
Research Site
Zaporozhye, Ukraine, 69600
United Kingdom
Research Site
London, United Kingdom, SE59RF
Research Site
Nottingham, United Kingdom, NG72UH
Research Site
Plymouth, United Kingdom, PL68DH
Research Site
Sheffield, United Kingdom, S102JF
Research Site
Stoke-on-Trent, United Kingdom, ST47LN
Sponsors and Collaborators
Biogen
AbbVie
Investigators
Study Director: Medical Director Biogen
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT01051349     History of Changes
Other Study ID Numbers: 205-MS-203  2009-015318-23 
Study First Received: January 15, 2010
Last Updated: August 15, 2016
Health Authority: Ukraine: State Expert Centre of the Ministry of Health of Ukraine
Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
India: Drugs Controller General of India
Germany: Paul-Ehrlich-Institut
Russia: Ministry of Health of the Russian Federation

Keywords provided by Biogen:
MS
Multiple Sclerosis

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Vaccines
Daclizumab
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents

ClinicalTrials.gov processed this record on September 23, 2016